Open AccessThis article is
- freely available
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Molecular Immunology Unit, Hospital Universitario Puerta de Hierro, Majadahonda, 28222 Madrid, Spain
* Author to whom correspondence should be addressed.
Received: 13 March 2013; in revised form: 6 June 2013 / Accepted: 19 June 2013 / Published: 27 June 2013
Abstract: Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials. However, current treatment regimens raise some issues that should be considered, such as the high cost of clinical-grade bispecific antibodies and the achievement of sustained therapeutic plasma levels. The use of gene transfer methods may circumvent problems related to large-scale production and purification, and result in sustained therapeutic plasma concentrations of the Fc-lacking bispecific antibodies. In fact, terminally differentiated cells and non-terminally differentiated cells can be genetically modified to secrete functionally active bispecific antibodies exerting clear anti-tumor effects. This review highlights the relevance of different promising strategies for in vivo delivery of therapeutic bispecific antibodies.
Keywords: bispecific antibodies; in vivo secretion; gene therapy; cell-based therapy; immunotherapeutic organoids; immunotherapeutic neovessels
Citations to this Article
Cite This Article
MDPI and ACS Style
Compte, M.; Nuñez-Prado, N.; Sanz, L.; Alvarez-Vallina, L. In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells. Antibodies 2013, 2, 415-425.
Compte M, Nuñez-Prado N, Sanz L, Alvarez-Vallina L. In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells. Antibodies. 2013; 2(3):415-425.
Compte, Marta; Nuñez-Prado, Natalia; Sanz, Laura; Alvarez-Vallina, Luis. 2013. "In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells." Antibodies 2, no. 3: 415-425.